Literature DB >> 19356923

Duration of symptoms, stage at diagnosis and relative survival in colon and rectal cancer.

Eivind Jullumstrø1, Stian Lydersen, Bjørn Møller, Olav Dahl, Tom-H Edna.   

Abstract

In colorectal cancer, the relation between duration of symptoms and stage at presentation and prognosis is not yet settled. All 1263 patients treated for colorectal cancer at Levanger Hospital, 1980-2004, and 2892 patients treated in Norway during 2004 were included. The association between symptom duration as an explanatory variable and tumour stage as a dependent variable was analysed using a proportional odds logistic regression model. Known duration of symptoms was divided into four categories: <1 week, 1-8 weeks, 2-6 months and >6 months. There was an inverse relationship between symptom duration and colon cancer TNM-stage, OR=0.73 (95% CI 0.63-0.84), p<0.001 (Levanger Hospital) and 0.84 (0.75-0.95), p=0.004 (Norway 2004), where the OR is per category of symptom duration. Duration of symptoms were also inversely associated with T-stage, N-stage and M-stage in colon cancer. These relationships were not found for rectal cancer. In colon cancer the relative five-year survival for the four intervals of symptom duration was 44%, 39%, 54% and 66%, p<0.001, in Levanger, 1980-2004, and four-year survival was 46%, 62%, 75% and 74%, p<0.001, in Norway 2004, respectively. For rectal cancer survival was not dependent on symptom duration. In a multivariate analysis of relative survival of patients with colon cancer, duration of symptoms was associated with survival independent of tumour differentiation and TNM-stage. Increasing duration of symptoms was positively associated with less advanced disease and better survival in colon cancer, but not in rectal cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19356923     DOI: 10.1016/j.ejca.2009.03.014

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  Multilevel Approaches to Reducing Diagnostic and Treatment Delay in Colorectal Cancer.

Authors:  Sherri Sheinfeld Gorin
Journal:  Ann Fam Med       Date:  2019-09       Impact factor: 5.166

2.  Fall of another myth for colon cancer: Duration of symptoms does not differ between right- or left-sided colon cancers.

Authors:  Ersin Öztürk; Mehmet Ayhan Kuzu; Derya Öztuna; Özgen Işık; Aras Emre Canda; Emre Balık; Serdar Erkasap; Tayfun Yoldaş; Cihangir Akyol; Sezai Demirbaş; Bünyamin Özoğul; Ömer Topçu; Ercan Gedik; Bilgi Baca; İlknur Ergüner; Oktar Asoğlu; Bülent Erkek; Tuncay Yılmazlar; Erhan Reis; Rasim Gençosmanoğlu; Ali Konan
Journal:  Turk J Gastroenterol       Date:  2019-08       Impact factor: 1.852

3.  Do diagnostic and treatment delays for colorectal cancer increase risk of death?

Authors:  Sandi L Pruitt; Amy Jo Harzke; Nicholas O Davidson; Mario Schootman
Journal:  Cancer Causes Control       Date:  2013-02-28       Impact factor: 2.506

4.  Chemotherapy use in stage III colon cancer: a National Cancer Database analysis.

Authors:  Smrity Upadhyay; Sumit Dahal; Vijaya Raj Bhatt; Nabin Khanal; Peter T Silberstein
Journal:  Ther Adv Med Oncol       Date:  2015-09       Impact factor: 8.168

5.  Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial.

Authors:  Glen Rb Irving; Chinenye Oo Iwuji; Bruno Morgan; David P Berry; William P Steward; Anne Thomas; Karen Brown; Lynne M Howells
Journal:  Trials       Date:  2015-03-24       Impact factor: 2.279

6.  Distance to hospital is not a risk factor for emergency colon cancer surgery.

Authors:  Niillas Blind; Karin Strigård; Ulf Gunnarsson; Fredrik Brännström
Journal:  Int J Colorectal Dis       Date:  2018-05-24       Impact factor: 2.571

7.  Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival.

Authors:  David Roder; Christos Stelios Karapetis; Ian Olver; Dorothy Keefe; Robert Padbury; James Moore; Rohit Joshi; David Wattchow; Dan L Worthley; Caroline Louise Miller; Carol Holden; Elizabeth Buckley; Kate Powell; Dianne Buranyi-Trevarton; Kellie Fusco; Timothy Price
Journal:  BMJ Open       Date:  2019-09-30       Impact factor: 2.692

8.  The impact of coronavirus disease 2019 on surveillance colonoscopies in South Australia.

Authors:  Molla M Wassie; Madelyn Agaciak; Charles Cock; Peter Bampton; Graeme P Young; Erin L Symonds
Journal:  JGH Open       Date:  2021-03-09

9.  N6‑methyladenosine upregulates miR‑181d‑5p in exosomes derived from cancer‑associated fibroblasts to inhibit 5‑FU sensitivity by targeting NCALD in colorectal cancer.

Authors:  Shengli Pan; Yingying Deng; Jun Fu; Yuhao Zhang; Zhijin Zhang; Xianju Qin
Journal:  Int J Oncol       Date:  2022-01-11       Impact factor: 5.650

10.  Effect of diagnostic delay on survival in patients with colorectal cancer: a retrospective cohort study.

Authors:  Salvador Pita-Fernández; Luis González-Sáez; Beatriz López-Calviño; Teresa Seoane-Pillado; Elena Rodríguez-Camacho; Alejandro Pazos-Sierra; Paloma González-Santamaría; Sonia Pértega-Díaz
Journal:  BMC Cancer       Date:  2016-08-22       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.